4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $171,710.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMTGet Free Report) insider Scott Bizily sold 6,244 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $27.50, for a total value of $171,710.00. Following the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at approximately $47,767.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock traded down $0.78 during mid-day trading on Monday, reaching $27.85. 1,930,662 shares of the stock traded hands, compared to its average volume of 1,591,509. The stock has a market capitalization of $1.19 billion, a PE ratio of -10.20 and a beta of 2.63. 4D Molecular Therapeutics, Inc. has a 12-month low of $9.44 and a 12-month high of $35.61. The business’s 50-day moving average is $19.69 and its 200-day moving average is $15.81.

4D Molecular Therapeutics (NASDAQ:FDMTGet Free Report) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.43. The company had revenue of $20.20 million during the quarter, compared to analysts’ expectations of $6.41 million. 4D Molecular Therapeutics had a negative return on equity of 34.73% and a negative net margin of 436.30%. Equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently bought and sold shares of the company. Bfsg LLC purchased a new stake in 4D Molecular Therapeutics during the fourth quarter valued at $30,000. US Bancorp DE grew its holdings in 4D Molecular Therapeutics by 580.7% during the fourth quarter. US Bancorp DE now owns 1,797 shares of the company’s stock valued at $36,000 after purchasing an additional 1,533 shares during the period. Lazard Asset Management LLC bought a new stake in 4D Molecular Therapeutics during the fourth quarter valued at about $48,000. International Assets Investment Management LLC bought a new stake in 4D Molecular Therapeutics during the third quarter valued at about $36,000. Finally, Royal Bank of Canada grew its holdings in 4D Molecular Therapeutics by 84.8% during the second quarter. Royal Bank of Canada now owns 3,223 shares of the company’s stock valued at $59,000 after purchasing an additional 1,479 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have commented on FDMT shares. SVB Leerink raised 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 target price for the company in a report on Wednesday, October 18th. Cantor Fitzgerald initiated coverage on 4D Molecular Therapeutics in a research note on Tuesday, October 24th. They issued an “overweight” rating and a $32.00 price target for the company. Leerink Partnrs upgraded 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Wednesday, October 18th. The Goldman Sachs Group restated a “buy” rating and issued a $81.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 7th. Finally, BMO Capital Markets boosted their price target on 4D Molecular Therapeutics from $50.00 to $70.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Read Our Latest Stock Analysis on 4D Molecular Therapeutics

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy.

Featured Stories

Insider Buying and Selling by Quarter for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.